Table 1.
Population demographics for patient serum samples
| Parameter | Control | Asthma | COPD |
|---|---|---|---|
| Maximum number | 104 | 514 | 219 |
| Percentage male | 37.5% | 44.9% | 62.7% |
| Mean age (yr)* | 50 ± 8 | 40 ± 12 | 68 ± 8 |
| Mean height (m) | 1.71 ± 0.08 | 1.74 ± 0.09 | 1.67 ± 0.88 |
| Mean weight (kg) | 76.35 ± 12.1 | 78.12 ± 15.7 | 70.23 ± 18.1 |
| Mean smoking (pack-yr)* | 10.50 ± 11.69 | 4.95 ± 9.58 | 46.87 ± 26.72 |
| FEV1 pre- (%Pred)* | 100.94 ± 10.99 | 80.71 ± 20.70 | 41.87 ± 18.52 |
| FEV1 post- (%Pred)* | 104.78 ± 11.32 | 92.42 ± 18.73 | 47.53 ± 19.39 |
| FEV1/VC pre-* | 0.80 ± 0.05 | 0.70 ± 0.14 | 0.45 ± 0.13 |
| FEV1/VC post-* | 0.82 ± 0.04 | 0.76 ± 0.12 | 0.45 ± 0.12 |
| Reversibility (% change in FEV1 from baseline to salbutamol)* | 3.91 ± 4.43 | 11.72 ± 7.10 | 6.64 ± 3.29 |
| BHR (PC20; mg/ml) | >32 | <32 | n/a |
Subjects were selected from the total pool based on presence of complete clinical data for phenotype analyses or genotype-specific quality control that excluded subjects. Pre- indicates measurements taken prior to the administration of a bronchodilator (salbutamol). Post- indicates measurements taken after the administration of a bronchodilator (salbutamol). BHR, bronchial hyperresponsiveness. Values are means ± sd.
*
P < 0.01 across groups.